

Amendments to the Claims:

This listing of claims will replace all prior versions and listings of claims in this application:

Listing of Claims:

Claims 1-8 (Cancelled).

Claim 9 (Currently amended): A method for treating an inflammatory component of a ~~disease selected from~~ cystic fibrosis, ~~idiopathic lung fibrosis and fibrosing alveolitis~~, which method comprises administering, via inhalation, a formulation wherein the active substance consists of a therapeutically effective amount of a salt of tiotropium, and, optionally, physiologically acceptable excipients, and wherein the salt of tiotropium provides an anti-inflammatory activity.

Claim 10 (Cancelled).

Claim 11 (Previously presented): The method as recited in claim 9 wherein the tiotropium salt has an anion selected from chloride, bromide, iodide, methanesulphonate, paratoluenesulphonate and methylsulphate.

Claim 12 (Previously presented): The method as recited in claim 11 wherein the anion of the tiotropium salt is methanesulphonate, chloride, bromide or iodide.

Claim 13 (Previously presented): The method as recited in claim 12 wherein the anion of the tiotropium salt is methanesulphonate or bromide.

Claim 14 (Previously presented): The method of claim 9, wherein the salt of tiotropium

is administered via inhalation in a formulation selected from powders for inhalation, metered-dose aerosols containing propellant gas and propellant-gas-free inhalable solutions.

Claim 15 (Previously presented): The method of claim 14, wherein the formulation is an inhalable powder which contains the tiotropium salt in admixture with a suitable physiologically acceptable excipient selected from monosaccharides, disaccharides, oligo- and polysaccharides, polyalcohols, salts, and mixtures thereof.

Claim 16 (Previously presented): The method of claim 14, wherein the formulation is an inhalable aerosol containing a propellant gas, which contains the tiotropium salt in dissolved or dispersed form.

Claim 17 (Previously presented): The method of claim 16, wherein the propellant gas is a hydrocarbon or halohydrocarbon gas.

Claim 18 (Previously presented): The method of claim 16, wherein the propellant gas is n-butane, isobutane, or a fluorinated methane, ethane, propane, butane, cyclopropane or cyclobutane.

Claim 19 (Previously presented): The method of claim 16, wherein the propellant gas is TG134a, TG227 or a mixture thereof.

Claim 20 (Previously presented): The method of claim 16, wherein the inhalable aerosol further comprises one or more other ingredients selected from co-solvents, stabilizers, surfactants, antioxidants, lubricants and pH adjusters.

Claim 21 (Previously presented): The method of claim 14, wherein the formulation is a

propellant-free inhalable solution which further comprises a solvent selected from water, ethanol or a mixture of water and ethanol.

Claim 22 (Previously presented): The method of claim 21, wherein the pH of the propellant-free inhalable solution is 2 - 7.

Claim 23 (Previously presented): The method of claim 21, wherein the propellant-free inhalable solution further comprises a co-solvent which contains hydroxyl groups or other polar groups.

Claim 24 (Cancelled).

Claim 25 (Previously presented): The method of claim 23, wherein the cosolvent is an alcohol or glycol.

Claim 26 (Previously presented): The method of claim 23, wherein the propellant-free inhalable solution further comprises at least one surfactant, stabilizer, complexing agent, antioxidant, preservative, flavoring, pharmacologically acceptable salt or vitamin.

Claim 27 (Previously presented): The method of claim 14, wherein the formulation further comprises, as complexing agent, editic acid or a salt of editic acid.

Claim 28 (Previously presented): The method of claim 14, wherein the formulation further comprises, as complexing agent, sodium edetate.

Claim 29 (Previously presented): The method of claim 21, wherein the propellant-free inhalable solution contains only benzalkonium chloride and sodium edetate in addition to the active substance and the solvent.

Appln. No.10/644,333
Reply dated January 28, 2011
In response to September 30, 2010 Final Office Action

Claim 30 (Previously presented): The method of claim 21, wherein the propellant-free inhalable solution is a concentrate or a sterile inhalable solution ready for use.

Claim 31 (Previously presented): The method as recited in claim 12 wherein the anion of the tiotropium salt is bromide.

Claim 32 (Cancelled).